Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

Table 1 Patient characteristics

	n = 265
Age in yr	68 (17-86)
≥ 75 yr	83 (31%)
Sex as male/female	150/115 (57%/43%)
Cirrhosis	91 (34%)
Moderate chronic kidney disease, eGFR < 60 mL/min/1.73 m2	53 (20%)
History of HCC treatment	33 (12%)
History of pegylated IFN + ribavirin therapy	39 (15%)
Height in cm	160.2 (134.0-182.0)
Weight in kg	58.0 (32.3-99.3)
BMI in kg/m2	22.6 (15.5-35.0)
Baseline HCV-RNA in logIU/mL	6.0 (1.4-7.4)
WBC as /mm3	5000 (1810-13260)
Hb in g/dL	13.6 (10.2-20.1)
Platelets as × 104/mm3	16.2 (4.6-38.9)
AST in IU/L	43 (12-257)
ALT in IU/L	39 (6-394)
γ-GT in IU/L	32 (5-898)
eGFR	73 (31-156)
AFP in ng/mL	4.3 (1.0-88.3)

Values are expressed as median (range) or numbers (percentage). γ-GT: γ-glutamyl transferase; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; eGFR: Estimated glomerular filtration rate; Hb: Hemoglobin; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HCV-RNA: Hepatitis C virus-ribonucleic acid; IFN: Interferon; WBC: White blood cells.